A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)

The purpose of this study is to research the effects, good or bad, of atezolizumab on your specific type of cancer (ovarian, fallopian tube, or primary peritoneal). Atezolizumab is an experimental drug. However, atezolizumab is approved in the United States (U.S.) for the treatment of locally advanced or metastatic bladder cancer (urothelial carcinoma) and non-small cell lung cancer that came back after getting platinum-containing chemotherapy.


This research study is led by Dr. Tashanna Myers.

Contact: Laura Sorci, 413-794-3188

Participation details:

March 01, 2017
Cancer-Gynecologic, Cancer
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA

Newly-diagnosed stage III/IV ovarian, fallopian tube, or primary peritoneal cancer

Interventional (Clinical Trial), Randomized